A PHASE II OPEN LABEL STUDY OF NEIHULIZUMAB, ANTI-CD162 (PSGL-1) ANTIBODY, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE, ANTI-TNF ALPHA AND/OR ANTI-INTEGRIN REFRACTORY ULCERATIVE COLITIS

neihulizumab (AbGn-168H) - AbGenomics

https://ddw.apprisor.org/epsSearchDDW.cfm

David T. Rubin2; Scott D. Lee3; Lucky Flores4; Gustavo Albizu-Angulo6; Ellen J. Scherl5; Surinder Saini7; Shipra Patel8; Yi-Lin I. Cheng9; Ting-Ying Cheng1; Shih-Yao Lin1

Jan 28, 2020